The TP53 signaling pathway (resistant: 80% vs. sensitive: 73%, p = 0.55) and the DNA‐damage response signaling pathway (resistant: 60% vs. sensitive: 36%, p = 0.26) had higher mutation rate in drug‐resistant recurrent ovarian cancer versus drug‐sensitive recurrent ovarian cancer. This evidence concerns the gene TP53 and ovarian carcinoma.